TR-701 FA + Linezolid
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Skin and Subcutaneous Tissue Bacterial Infections
Conditions
Skin and Subcutaneous Tissue Bacterial Infections
Trial Timeline
Sep 15, 2011 → Jan 10, 2013
NCT ID
NCT01421511About TR-701 FA + Linezolid
TR-701 FA + Linezolid is a phase 3 stage product being developed by Merck for Skin and Subcutaneous Tissue Bacterial Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT01421511. Target conditions include Skin and Subcutaneous Tissue Bacterial Infections.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01421511 | Phase 3 | Completed |
| NCT01170221 | Phase 3 | Completed |
Competing Products
20 competing products in Skin and Subcutaneous Tissue Bacterial Infections